

Joan ClÀria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9256449/publications.pdf>

Version: 2024-02-01

158
papers

17,212
citations

18436

62
h-index

14702

127
g-index

163
all docs

163
docs citations

163
times ranked

24338
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , 1993, 105, 229-236.	0.6	820
3	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550
4	Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω -3 fatty acids: a role for resolvins and protectins. <i>FASEB Journal</i> , 2009, 23, 1946-1957.	0.2	511
5	Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases. <i>Cell Metabolism</i> , 2014, 19, 21-36.	7.2	378
6	Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype. <i>Journal of Immunology</i> , 2011, 187, 5408-5418.	0.4	360
7	Role for PPAR γ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. <i>FASEB Journal</i> , 2011, 25, 2538-2550.	0.2	325
8	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
9	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	1.8	223
10	Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. <i>Gastroenterology</i> , 2002, 122, 85-93.	0.6	222
11	Resolvin D1 and Resolvin D2 Govern Local Inflammatory Tone in Obese Fat. <i>Journal of Immunology</i> , 2012, 189, 2597-2605.	0.4	222
12	Cyclooxygenase-2 Biology. <i>Current Pharmaceutical Design</i> , 2003, 9, 2177-2190.	0.9	209
13	Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. <i>FASEB Journal</i> , 2003, 17, 1986-1995.	0.2	204
14	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 670-685.	1.8	204
15	Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. <i>Hepatology</i> , 1992, 15, 343-349.	3.6	201
16	Circulating levels of endothelin in cirrhosis. <i>Gastroenterology</i> , 1993, 104, 1485-1491.	0.6	198
17	Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17 β -hydroxy-DHA. <i>FASEB Journal</i> , 2006, 20, 2537-2539.	0.2	194
18	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	6.1	190

#	ARTICLE	IF	CITATIONS
19	Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 536-541.	3.3	185
20	Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549) and Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation. <i>Molecular Medicine</i> , 1996, 2, 583-596.	1.9	183
21	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	0.6	178
22	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
23	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. <i>Journal of Hepatology</i> , 2021, 75, S49-S66.	1.8	146
24	Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. <i>Hepatology</i> , 1993, 18, 367-372.	3.6	142
25	5-Lipoxygenase Activating Protein Signals Adipose Tissue Inflammation and Lipid Dysfunction in Experimental Obesity. <i>Journal of Immunology</i> , 2010, 184, 3978-3987.	0.4	139
26	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. <i>Hepatology</i> , 1993, 17, 788-793.	3.6	136
27	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
28	The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPAR γ activation. <i>FASEB Journal</i> , 2005, 19, 1120-1122.	0.2	129
29	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. <i>Hepatology</i> , 1994, 20, 839-844.	3.6	124
30	5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. <i>FASEB Journal</i> , 2001, 15, 2326-2336.	0.2	118
31	Diversity of lipid mediators in human adipose tissue depots. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 304, C1141-C1149.	2.1	112
32	Molecular interplay between Δ^5/Δ^6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. <i>Gut</i> , 2014, 63, 344-355.	6.1	107
33	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016, 65, 1535-1545.	6.1	103
34	Prostaglandin E2 Exerts Multiple Regulatory Actions on Human Obese Adipose Tissue Remodeling, Inflammation, Adaptive Thermogenesis and Lipolysis. <i>PLoS ONE</i> , 2016, 11, e0153751.	1.1	98
35	Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis. <i>FASEB Journal</i> , 2014, 28, 836-848.	0.2	97
36	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. <i>Gastroenterology</i> , 2002, 122, 387-393.	0.6	96

#	ARTICLE	IF	CITATIONS
37	Cell-specific PPAR β deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. <i>Journal of Hepatology</i> , 2013, 59, 1045-1053.	1.8	91
38	The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. <i>Journal of Immunology</i> , 2016, 197, 3755-3761.	0.4	91
39	Increased Levels of 12(S)-HETE in Patients With Essential Hypertension. <i>Hypertension</i> , 2001, 37, 334-338.	1.3	89
40	Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure. <i>Cells</i> , 2020, 9, 1175.	1.8	89
41	Nitric oxide production in arterial vessels of cirrhotic rats. <i>Hepatology</i> , 1995, 21, 554-560.	3.6	88
42	Signaling and Immunoresolving Actions of Resolvin D1 in Inflamed Human Visceral Adipose Tissue. <i>Journal of Immunology</i> , 2016, 197, 3360-3370.	0.4	87
43	Increased nitric oxide α dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. <i>Hepatology</i> , 1994, 20, 1615-1621.	3.6	86
44	5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor α -induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. <i>Hepatology</i> , 2010, 51, 817-827.	3.6	86
45	Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites. <i>Seminars in Liver Disease</i> , 1994, 14, 44-58.	1.8	85
46	Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer. <i>Current Pharmaceutical Design</i> , 2005, 11, 3431-3447.	0.9	83
47	Orchestration of Tryptophan α Kynurenine Pathway, Acute Decompensation, and Acute α Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	3.6	80
48	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. <i>Hepatology</i> , 2005, 41, 579-587.	3.6	79
49	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. <i>Gastroenterology</i> , 1991, 100, 494-501.	0.6	78
50	Efficacy of Albumin Treatment for Patients with Cirrhosis α Infections Unrelated to Spontaneous Bacterial α Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	2.4	77
51	Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. <i>European Journal of Pharmacology</i> , 2016, 785, 133-143.	1.7	73
52	Coordinate Functional Regulation between Microsomal Prostaglandin E Synthase-1 (mPGES-1) and Peroxisome Proliferator-activated Receptor β (PPAR β) in the Conversion of White-to-brown Adipocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 28230-28242.	1.6	72
53	Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. <i>Journal of Leukocyte Biology</i> , 2018, 105, 25-36.	1.5	72
54	Carbon tetrachloride induced cirrhosis in rats: A useful tool for investigating the pathogenesis of ascites in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1992, 7, 90-97.	1.4	70

#	ARTICLE	IF	CITATIONS
55	Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis. <i>Hepatology</i> , 2018, 68, 1937-1952.	3.6	70
56	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. <i>Gastroenterology</i> , 2000, 119, 794-805.	0.6	69
57	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. <i>Hepatology</i> , 1999, 29, 1057-1063.	3.6	68
58	Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. <i>FASEB Journal</i> , 2003, 17, 1745-1747.	0.2	67
59	Resolution of inflammation in obesity-induced liver disease. <i>Frontiers in Immunology</i> , 2012, 3, 257.	2.2	67
60	Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G553-G562.	1.6	66
61	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. <i>Hepatology</i> , 1995, 22, 915-920.	3.6	65
62	Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure. <i>Cells</i> , 2020, 9, 2632.	1.8	65
63	Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. <i>Molecular and Cellular Endocrinology</i> , 2016, 419, 44-59.	1.6	64
64	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. <i>Gastroenterology</i> , 1989, 97, 1294-1299.	0.6	63
65	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , 1993, 17, 800-806.	3.6	63
66	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1998, 115, 147-156.	0.6	63
67	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. <i>Gastroenterology</i> , 1999, 116, 1167-1175.	0.6	61
68	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. <i>Hepatology</i> , 1994, 20, 948-954.	3.6	60
69	Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. <i>Gastroenterology</i> , 1995, 108, 1842-1848.	0.6	59
70	Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 52, 1980-1991.	3.6	59
71	Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor β -mediated CINC1 release in rat liver cells: novel actions of lipoxin A4(LXA4) and ASA-triggered 15-epi-LXA4. <i>FASEB Journal</i> , 2002, 16, 1937-1939.	0.2	58
72	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 113-120.	1.8	58

#	ARTICLE	IF	CITATIONS
73	Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. <i>Journal of Leukocyte Biology</i> , 2005, 78, 871-878.	1.5	56
74	Resolution of Adipose Tissue Inflammation. <i>Scientific World Journal, The</i> , 2010, 10, 832-856.	0.8	56
75	The specialized proresolving lipid mediator maresin 1 protects hepatocytes from lipotoxic and hypoxia-induced endoplasmic reticulum stress. <i>FASEB Journal</i> , 2017, 31, 5384-5398.	0.2	56
76	The results in rodent models of atherosclerosis are not interchangeable. <i>Atherosclerosis</i> , 2007, 195, e85-e92.	0.4	55
77	Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-10.	0.8	55
78	New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 297-309.	1.0	53
79	The soluble guanylate cyclase stimulator GW4268773 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. <i>British Journal of Pharmacology</i> , 2018, 175, 953-967.	2.7	53
80	Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 778-786.	1.3	52
81	The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011, 14, 347-353.	1.3	52
82	Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2022, 76, 93-106.	1.8	51
83	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 817-828.	1.8	48
84	Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	47
85	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47
86	Hepatocytes are a rich source of novel aspirin-triggered 15-epi-lipoxin A ₄ . <i>American Journal of Physiology - Cell Physiology</i> , 1999, 277, C870-C877.	2.1	46
87	Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. <i>Journal of Lipid Research</i> , 2008, 49, 2513-2523.	2.0	45
88	Leukocytes from obese individuals exhibit an impaired SPM signature. <i>FASEB Journal</i> , 2019, 33, 7072-7083.	0.2	45
89	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	1.8	45
90	Aquaretic effect of the μ -opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. <i>Gastroenterology</i> , 1995, 109, 217-223.	0.6	44

#	ARTICLE	IF	CITATIONS
91	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. <i>British Journal of Pharmacology</i> , 2002, 135, 891-900.	2.7	43
92	Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. <i>FASEB Journal</i> , 2020, 34, 10640-10656.	0.2	43
93	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. <i>Hepatology</i> , 1995, 22, 479-487.	3.6	41
94	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. <i>Gastroenterology</i> , 2007, 133, 2019-2028.	0.6	41
95	Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis. <i>Hepatology</i> , 1991, 13, 585-589.	3.6	40
96	The pathogen receptor liver and lymph node sinusoidal endothelial cell C-type lectin is expressed in human Kupffer cells and regulated by PU.1. <i>Hepatology</i> , 2009, 49, 287-296.	3.6	40
97	New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. <i>Frontiers in Immunology</i> , 2011, 2, 49.	2.2	40
98	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 69.	2.2	40
99	Polymorphisms in the IL1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology</i> , 2017, 65, 202-216.	3.6	39
100	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. <i>Frontiers in Immunology</i> , 2020, 11, 619039.	2.2	39
101	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. <i>Hepatology</i> , 2006, 43, 444-453.	3.6	38
102	A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. <i>Kidney International</i> , 2006, 69, 526-530.	2.6	35
103	Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. <i>Liver International</i> , 2018, 38, 875-884.	1.9	35
104	The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification. <i>Cardiovascular Research</i> , 2019, 115, 1557-1566.	1.8	35
105	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPAR β . Influence of albumin. <i>Journal of Hepatology</i> , 2005, 42, 75-81.	1.8	34
106	F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: Effect of glycemic control. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1118-1120.	1.5	33
107	Regulation of Cell Proliferation and Apoptosis by Bioactive Lipid Mediators. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 369-382.	0.8	33
108	Pro-resolving actions of SPM in adipose tissue biology. <i>Molecular Aspects of Medicine</i> , 2017, 58, 83-92.	2.7	33

#	ARTICLE	IF	CITATIONS
109	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. <i>Journal of Immunology</i> , 2020, 205, 2840-2849.	0.4	33
110	Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 107, 77-84.	1.0	32
111	Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF- κ B/NLRP3 inflammasome circuit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28263-28274.	3.3	31
112	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 1116-1127.	1.8	31
113	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. <i>Hepatology</i> , 1999, 30, 501-509.	3.6	30
114	New Insights into the Regulation of Liver Inflammation and Oxidative Stress. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 1321-1330.	1.1	30
115	Smoking increases serum levels of transforming growth factor-beta in diabetic patients. <i>Diabetes Care</i> , 1999, 22, 1915-1916.	4.3	28
116	Prostaglandin E ₂ signals white-to-brown adipogenic differentiation. <i>Adipocyte</i> , 2014, 3, 290-296.	1.3	27
117	Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. <i>Scientific Reports</i> , 2017, 7, 15724.	1.6	27
118	Increased apoptosis dependent on caspase-3 activity in polymorphonuclear leukocytes from patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2004, 41, 44-48.	1.8	26
119	Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. <i>Kidney International</i> , 1991, 40, 182-187.	2.6	25
120	Protection from hepatic lipid accumulation and inflammation by genetic ablation of 5-lipoxygenase. <i>Prostaglandins and Other Lipid Mediators</i> , 2010, 92, 54-61.	1.0	22
121	Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia. <i>Frontiers in Pharmacology</i> , 2018, 9, 1327.	1.6	22
122	Prostaglandins and other cyclooxygenase-dependent arachidonic acid metabolites and the kidney in liver disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2003, 72, 19-33.	1.0	21
123	Natriuretic hormone activity in the urine of cirrhotic patients. <i>Hepatology</i> , 1990, 12, 467-475.	3.6	19
124	Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis. <i>Journal of Hepatology</i> , 1994, 21, 521-526.	1.8	19
125	An investigation of the resolution of inflammation (catabasis) in COPD. <i>Respiratory Research</i> , 2012, 13, 101.	1.4	19
126	Albumin protects the liver from tumor necrosis factor α -induced immunopathology. <i>FASEB Journal</i> , 2021, 35, e21365.	0.2	15

#	ARTICLE	IF	CITATIONS
127	Hepatic inflammasome activation as origin of Interleukin-1 β and Interleukin-1 γ in liver cirrhosis. <i>Gut</i> , 2021, 70, 1799-1800.	6.1	14
128	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	2.2	13
129	Liver: The formation and actions of aspirin-triggered lipoxins. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005, 73, 277-282.	1.0	12
130	Proresolving lipid mediators and liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 159023.	1.2	11
131	Reduced Plasma Extracellular Vesicle CD5L Content in Patients With Acute-On-Chronic Liver Failure: Interplay With Specialized Pro-Resolving Lipid Mediators. <i>Frontiers in Immunology</i> , 2022, 13, 842996.	2.2	11
132	Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. <i>Liver International</i> , 2020, 40, 646-653.	1.9	10
133	Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease. <i>Hepatology</i> , 2023, 77, 1303-1318.	3.6	10
134	Mitochondrial Dysfunction in Advanced Liver Disease: Emerging Concepts. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 772174.	1.6	9
135	Natural killer cell recognition and killing of activated hepatic stellate cells. <i>Gut</i> , 2012, 61, 792-793.	6.1	8
136	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	1.8	8
137	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0222840.	1.1	7
138	Reply:. <i>Hepatology</i> , 2005, 42, 238-238.	3.6	6
139	Principles, Mechanisms of Action, and Future Prospects of Anti-inflammatory Drugs. , 2016, , 17-34.		6
140	Acute-on-Chronic Liver Failure, Human Serum Albumin, and Immune Modulation: The Beginning of an Exciting Adventure. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 633-636.	2.4	6
141	Albumin Lipidomics Reveals Meaningful Compositional Changes in Advanced Cirrhosis and Its Potential to Promote Inflammation Resolution. <i>Hepatology Communications</i> , 2022, 6, 1443-1456.	2.0	6
142	Resolution of Acute Inflammation and the Role of Lipid Mediators. <i>Scientific World Journal</i> , The, 2010, 10, 1553-1555.	0.8	5
143	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. <i>Comparative Hepatology</i> , 2004, 3, S19.	0.9	4
144	Aspirin in the 21st centuryâ€”common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK. <i>Ecanermedscience</i> , 2015, 9, 581.	0.6	4

#	ARTICLE	IF	CITATIONS
145	The Role of Inflammatory Mediators in Liver Failure. , 2011, , 131-153.		4
146	Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. Journal of Hepatology, 2006, 45, 221-229.	1.8	3
147	New Perspectives in the Modulation of the Eicosanoid Cascade in Inflammation. Letters in Drug Design and Discovery, 2005, 2, 391-402.	0.4	2
148	Resolvins, protectins and other lipid mediators in obesity-associated inflammatory disorders. Drug Discovery Today Disease Mechanisms, 2010, 7, e219-e225.	0.8	2
149	Blunted natriuretic response to human urine extracts with Na ⁺ , K ⁺ -ATPase inhibiting activity in experimental cirrhosis. Journal of Hepatology, 1994, 20, 660-665.	1.8	1
150	Editorial. Prostaglandins and Other Lipid Mediators, 2015, 121, 1-3.	1.0	1
151	Liver Failure, Acute-on-Chronic. , 2020, , 436-443.		1
152	Sodium in preascitic cirrhosis: please pass the salt. Gut, 2001, 49, 748-749.	6.1	0
153	Aplicación de la secuenciación masiva de nueva generación al diagnóstico molecular de la hipercolesterolemia familiar. Revista Del Laboratorio Clínico, 2015, 8, 8-18.	0.1	0
154	Editorial "Special issue of the 6th European Workshop on Lipid Mediators. Prostaglandins and Other Lipid Mediators, 2017, 133, 1-3.	1.0	0
155	Leveraging omics to understand the molecular basis of acute-on-chronic liver failure. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, .	0.1	0
156	Aspirin-Triggered 15-Epi-Lipoxin A4 Biosynthesis in Rat Liver Cells. Advances in Experimental Medicine and Biology, 2002, 507, 199-209.	0.8	0
157	Renal Effects of Selective Cyclooxygenase Inhibition in Experimental Liver Disease. Advances in Experimental Medicine and Biology, 2003, 525, 133-136.	0.8	0
158	La aplicación de las ómicas para comprender la base molecular de la insuficiencia hepática aguda sobre crónica. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 528-540.	0.1	0